Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases with unmet medical needs. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryteâ„¢, a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryteâ„¢ and is now negotiating a confirmatory Phase 3 pivotal study design with the US Food & Drug Administration, while also evaluating/pursuing potential HyBryteâ„¢ marketing approval ex-U.S. with the successfully completed Phase 3 study. Visit SNGXinfo.com to learn more.
-
3:15
RedChip
1 year agoSoligenix: Advancing Rare Disease Treatments and Fighting Emerging Diseases
6 -
48:58
RedChip
10 months agoSoligenix: Illuminating the Future of Rare Disease Therapies
5 -
2:38
Asher Press
1 year agoPfizer CEO Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
170 -
2:42
xenia1
5 months agoA 200 billion vaccine enterprise would have collapsed if Fauci had admitted...
73 -
4:13
The Igonrant Entrepreneur
11 months agoThe First AI-Generated Drug Enters Human Trials, Pioneering a New Era in Medicine!
22 -
2:38
Truthseekers17
1 year agoPfizer CEO Albert Burla Announces $43 Billion Acquisition of Seagen Cancer Biotechnology
33 -
2:04
Real Truth Real News
1 year ago💥 HUGE! Hydroxychloroquine Allows Viruses to Attack Cancer Cells While Leaving Healthy Cells, Healthy....
7.31K20 -
2:53
AMERICAXPOSED
1 year agoPfizer CEO Albert Bourla Announces Acquisition of Cancer Treatment Biotech Seagen For $43 Billion
208 -
1:38
RaisingAwareness
1 year agoDr. Ryan Cole: The Entire Lipid Nanoparticle Platform Needs to End
141 -
59:14
Life Lessons with Dr. Bob
4 months agoEp44 The BIG Money of BIG Pharma with Dr. Aaron Goodman
45